Log in to save to my catalogue

Acriflavine, a clinically aproved drug, inhibits SARS-CoV-2 and other betacoronaviruses

Acriflavine, a clinically aproved drug, inhibits SARS-CoV-2 and other betacoronaviruses

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2504852069

Acriflavine, a clinically aproved drug, inhibits SARS-CoV-2 and other betacoronaviruses

Publication information

Publisher

Cold Spring Harbor: Cold Spring Harbor Laboratory Press

More information

Scope and Contents

Contents

Summary The COVID-19 pandemic caused by SARS-CoV-2 has been socially and economically devastating. Despite an unprecedented research effort, effective therapeutics are still missing to limit severe disease and mortality. Using high-throughput screening, we identified acriflavine as a potent papain-like protease (PLpro) inhibitor. NMR titrations and...

Alternative Titles

Full title

Acriflavine, a clinically aproved drug, inhibits SARS-CoV-2 and other betacoronaviruses

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2504852069

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2504852069

Other Identifiers

E-ISSN

2692-8205

DOI

10.1101/2021.03.20.436259